<document id="10.1.1.1.1516"><title src="SVM HeaderParse 0.1">Acta Crystallographica Section B Structural Science</title><abstract src="SVM HeaderParse 0.1">Structural features controlling the binding of bcarbolines to the benzodiazepine receptor-Carbolines are a class of drug which can interact with a high af®nity with the benzodiazepine (BDZ) binding site of the GABAA receptor. The present paper, aimed at obtaining a deeper insight into the structure±properties relationships of this class of molecules, reports the crystal structures of four-carbolines: ZK93423 (3-carboethoxy-4-methoxymethyl-6benzyloxy--carboline), ZK91296 (3-carboethoxy-4-methoxymethyl-5-benzyloxy-</abstract><keywords></keywords><authors><author id="4200"><name src="SVM HeaderParse 0.1">Valeria Ferretti</name><address src="SVM HeaderParse 0.1">and b Dipartimento di</address><order>1</order></author><author id="4201"><name src="SVM HeaderParse 0.1">A Paola Gilli A</name><order>2</order></author><author id="4202"><name src="SVM HeaderParse 0.1">Pier Andrea Borea B</name><order>3</order></author><author id="4203"><name src="SVM HeaderParse 0.1">A Centro Di</name><address src="SVM HeaderParse 0.1">UniversitaÁ di Ferrara, I-44100 Ferrara, Italy</address><email src="SVM HeaderParse 0.1">Correspondence frt@unife.it</email><order>4</order></author></authors><citations src="ParsCit 1.0"><citation id="28474"><authors>F H Allen</authors><venue>Acta Cryst</venue><venType>JOURNAL</venType><year>2002</year><pages>380--388</pages><volume>58</volume><raw>Allen, F. H. (2002). Acta Cryst. B58, 380±388.</raw><contexts><context>- CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from the Cambridge Crystallographic Database (Allen, 2002) and by the structures of -CCE (IAG), 6-PBC (pAG) PRCC and ZK93426 (both ANTs), which, not being available as crystal structures, have been obtained by molecular±mechanics simulations. The structural</context><context>±4. Hydrogen-bonding parameters for the four structures are reported in Table 3. A total of 17 carboline structures have been retrieved from the Cambridge Structural Database (September 2003 version; Allen, 2002), from which seven compounds [CITRIG01,02,10 ( -CCM): Bertolasi et al., 1984; Kubicki &amp; Codding, 2001; Muir &amp; Codding, 1985; CITROM10: Muir &amp; Codding, 1984; JAFFIF ( -CC t Bu): Codding et al., 1988; </context></contexts></citation><citation id="28475"><authors>A Altomare,M C Burla,M Camalli,G Cascarano,C Giacovazzo,A Guagliardi,A G Moliterni,G Polidori</authors><venue>J. Appl. Cryst</venue><venType>JOURNAL</venType><year>1999</year><pages>115--121</pages><volume>32</volume><raw>Altomare, A., Burla, M. C., Camalli, M., Cascarano, G., Giacovazzo, C., Guagliardi, A., Moliterni, A. G., Polidori, G. &amp; Spagna, R. (1999). J. Appl. Cryst. 32, 115±121.</raw><contexts><context>diffractometer using graphite-monochromated Mo K radiation ( = 0.71069 A Ê ). Intensities were corrected for Lorentz and polarization. Structures were solved by direct methods with the SIR97 program (Altomare et al., 1999) and re®ned by full-matrix least-squares with anisotropic non-H and isotropic research papers Crystal data Chemical formula C23H22N2O4 C23H22N2O4 C13H11N3O [C13H13N2O] + Cl 1/2H2O Mr 390.43 390.43 22</context><context> 0.18, 0.18 Flack (1983) 0.18, 0.19 ± 0.28, 0.36 ± Flack parameter 1.4 (13) 1.7 (15) ± ± Computer programs used: Kappa CCD server software (Nonius, 1997), DENZO-SMN (Otwinowski &amp; Minor, 1997), SIR97 (Altomare et al., 1999), SHELXL97 (Sheldrick, 1997), ORTEPIII (Burnett &amp; Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the SHELXL97 (Sheldrick, 1997) program. All other calculations were perfor</context></contexts></citation><citation id="28476"><authors>Valeria</authors><title>Ferretti et al. Binding of -carbolines Acta Cryst</title><year>2004</year><publisher>Press</publisher><pubAddress>Oxford: Clarendon</pubAddress><volume>60</volume><raw>488 Valeria Ferretti et al. Binding of -carbolines Acta Cryst. (2004). B60, 481±489 Bernstein, J. (2002). Polymorphism in Molecular Crystals. Oxford: Clarendon Press.</raw></citation><citation id="28477"><authors>V Bertolasi,V Ferretti,G Gilli</authors><title>Acta Cryst</title><venType>TECHREPORT</venType><year>1984</year><tech>C40</tech><raw>Bertolasi, V., Ferretti, V., Gilli, G. &amp; Borea, P. A. (1984). Acta Cryst. C40, 1981±1983.</raw><contexts><context> This set of structural data is completed by the X-ray structures of other carbolines of known biological activity [DMCM (IAG: Bertolasi et al., 1990); Abecarnil (pAG: Bock et al., 1994); - CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from the Cambridge Crystallographic Database (Allen, 2002) and by the structures</context><context>ed in Table 3. A total of 17 carboline structures have been retrieved from the Cambridge Structural Database (September 2003 version; Allen, 2002), from which seven compounds [CITRIG01,02,10 ( -CCM): Bertolasi et al., 1984; Kubicki &amp; Codding, 2001; Muir &amp; Codding, 1985; CITROM10: Muir &amp; Codding, 1984; JAFFIF ( -CC t Bu): Codding et al., 1988; SEKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Bindi</context><context> are reported in Table 3. Interestingly, this bifurcated bond is the most common in 3-substituted carboline crystals, as it occurs in the structures of Abecarnil, DMCM (Bertolasi et al., 1990), -CCM (Bertolasi et al., 1984) and -CC t Bu (Codding et al., 1988); consequently, it can be argued that a similar interaction could play a role in the ligand±receptor binding. In (3) (FG7142) the 3-R moiety is replaced by a CONHC</context></contexts></citation><citation id="28478"><authors>V Bertolasi,V Ferretti,G Gilli</authors><venue>J. Chem. Soc. Perkin Trans</venue><venType>JOURNAL</venType><year>1990</year><pages>283--289</pages><volume>2</volume><raw>Bertolasi, V., Ferretti, V., Gilli, G. &amp; Borea, P. A. (1990). J. Chem. Soc. Perkin Trans 2, pp. 283±289.</raw><contexts><context>f®nity ligand harmine hydrochloride [1-methyl-7-methoxy- -carboline (4)]. This set of structural data is completed by the X-ray structures of other carbolines of known biological activity [DMCM (IAG: Bertolasi et al., 1990); Abecarnil (pAG: Bock et al., 1994); - CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from th</context><context>ing, 1985; CITROM10: Muir &amp; Codding, 1984; JAFFIF ( -CC t Bu): Codding et al., 1988; SEKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Binding of -carbolines 483sresearch papers Bertolasi et al., 1990; YERRUI, 01,02 (Abecarnil): Bock et al., 1994; ZERHOT, ZERHUT, Codding et al., 1995)], sketched in (II), display some activity with respect to the BDZ receptor. The Free±Wilson method (Free &amp; Wilson,</context><context>h respect to N1 has been chosen because it is systematically more stable by 8± 12 kJ mol 1 in agreement with the great majority of crystal structures so far determined (the only exception being DMCM: Bertolasi et al., 1990) and because it is generally believed to be the active conformation in drug binding (Dorey et al., 1989). 3. Results and discussion 3.1. Structural results ORTEPIII (Burnett &amp; Johnson, 1996) views of</context><context>g the crystal, whose parameters are reported in Table 3. Interestingly, this bifurcated bond is the most common in 3-substituted carboline crystals, as it occurs in the structures of Abecarnil, DMCM (Bertolasi et al., 1990), -CCM (Bertolasi et al., 1984) and -CC t Bu (Codding et al., 1988); consequently, it can be argued that a similar interaction could play a role in the ligand±receptor binding. In (3) (FG7142) the 3-</context></contexts></citation><citation id="28479"><authors>M Bock,G Depke,U Egner,A Mueller-Fahrnow</authors><venue>Tetrahedron</venue><venType>JOURNAL</venType><year>1994</year><pages>13125--13134</pages><volume>50</volume><raw>Bock, M., Depke, G., Egner, U., Mueller-Fahrnow, A. &amp; Winter, G. (1994). Tetrahedron, 50, 13125±13134.</raw><contexts><context>thyl-7-methoxy- -carboline (4)]. This set of structural data is completed by the X-ray structures of other carbolines of known biological activity [DMCM (IAG: Bertolasi et al., 1990); Abecarnil (pAG: Bock et al., 1994); - CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from the Cambridge Crystallographic Databas</context><context> -CC t Bu): Codding et al., 1988; SEKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Binding of -carbolines 483sresearch papers Bertolasi et al., 1990; YERRUI, 01,02 (Abecarnil): Bock et al., 1994; ZERHOT, ZERHUT, Codding et al., 1995)], sketched in (II), display some activity with respect to the BDZ receptor. The Free±Wilson method (Free &amp; Wilson, 1964) is a multiple regression technique for </context><context>.1 (2) ; ZK91296: N1Ð C1ÐC21ÐO4 142.3 (3) ], because of the repulsion exerted by the 4-methoxymethyl substituent, in agreement with Abecarnil, the only other 4-substituted structure found in the CSD (Bock et al., 1994), showing an out-of-plane rotation of some 30 . In all other 4-unsubstituted carbolines the ester group is coplanar with ring A to within 10 . Conversely, 1 Supplementary data for this paper are avai</context><context>B) of ring C by a large hydrophobic group with much conformational freedom, evidenced by the comparison of their crystal structures. Abecarnil, in particular, crystallizes in three polymorphic forms (Bock et al., 1994) in which the 6-benzyloxy group adopts different conformations, providing a good example of conformational polymorphism according to Bernstein's de®nition (Bernstein, 2002). According to the model of</context></contexts></citation><citation id="28480"><authors>P A Borea</authors><venue>Biochem. Pharmacol</venue><venType>JOURNAL</venType><year>1986</year><pages>283--9</pages><volume>35</volume><raw>Borea, P. A. &amp; Ferretti, V. (1986). Biochem. Pharmacol. 35, 2836± 2839.</raw></citation><citation id="28481"><authors>P A Borea,G Gilli,V Bertolasi</authors><year>1987</year><pages>334--344</pages><volume>31</volume><raw>Borea, P. A., Gilli, G., Bertolasi, V. &amp; Ferretti, V. (1987). Mol. Pharmacol. 31, 334±344.</raw><contexts><context>e the stereochemical features controlling binding and the intrinsic-activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference to the stereochemical</context><context>he right IAG behaviour [see (Ia)]; different balancing of the two forces produces any intermediate behaviour, pure ANTs representing only the point of perfect equilibrium of the two driving forces?' (Borea et al., 1987). A schematic stereochemical representation of the model is given in (I), where some BDZ±receptor ligands, oriented accordingly, are reported. In (a) the full agonist Oxazepam and the antagonist CGS8</context></contexts></citation><citation id="28482"><authors>C Braestrup,M Nielsen,T HonoreÁ,L H Jensen</authors><venue>Neuropharmacology</venue><venType>JOURNAL</venType><year>1983</year><pages>1451--1457</pages><volume>22</volume><raw>Braestrup, C., Nielsen, M., HonoreÁ, T., Jensen, L. H. &amp; Petersen, E. M. (1983). Neuropharmacology, 22, 1451±1457.</raw><contexts><context>Z binding site of the GABAA receptor. Here they are able to display different pharmacological properties by acting as full (fAG) or partial (pAG) agonists, inverse agonists (IAG) or antagonists (ANT; Braestrup et al., 1983). The agonists are known to allosterically modulate the binding of GABA ( -aminobutyric acid) to its receptor, increasing GABAergic transmission and producing anxiolytic, anticonvulsant, sedative±hyp</context></contexts></citation><citation id="28483"><authors>A Buhr,M T Schaerer,R Baur</authors><year>1997</year><pages>676--682</pages><volume>52</volume><raw>Buhr, A., Schaerer, M. T., Baur, R. &amp; Sigel, E. (1997). Mol. Pharmacol. 52, 676±682.</raw><contexts><context>ceptor interactions by means of af®nity experiments on mutated Received 20 May 2004 Accepted 4 June 2004 Acta Cryst. (2004). B60, 481±489 DOI: 10.1107/S0108768104013564 481sresearch papers receptors (Buhr et al., 1997; Schaerer et al., 1998; Davies et al., 1998; Sigel et al., 1998; Dunn et al., 1999; Renard et al., 1999; Strakhova et al., 2000; Newell et al., 2000). These experiments might eventually con®rm the pr</context></contexts></citation><citation id="28484"><authors>M N Burnett</authors><venType>TECHREPORT</venType><year>1996</year><pubAddress>Ridge, Tennessee, USA</pubAddress><tech>ORTEPIII. Report ORNL6895</tech><raw>Burnett, M. N. &amp; Johnson, C. K. (1996). ORTEPIII. Report ORNL6895. Oak Ridge National Laboratory, Oak Ridge, Tennessee, USA.</raw></citation><citation id="28485"><authors>P W Codding</authors><year>1983</year><pages>529--532</pages><volume>61</volume><raw>Codding, P. W. (1983). Can. J. Chem. 61, 529±532.</raw><contexts><context>19). Services for accessing these data are described at the back of the journal. hydrogenation of this ring induces the molecule to adopt a `butter¯y' non-planar conformation (Borea &amp; Ferretti, 1986; Codding, 1983) in which the ester substituent is nearly perpendicular to the mean plane of the ring, leading to the Figure 1 ORTEPIII (Burnett &amp; Johnson, 1996) view and atom numbering for ZK93423 (1). The displacm</context></contexts></citation><citation id="28486"><authors>A K S Muir</authors><year>1985</year><pages>178--184</pages><volume>28</volume><raw>Codding, P. W. &amp;. Muir, A. K. S (1985). Mol. Pharmacol. 28, 178±184.</raw><contexts><context>o rationalize the stereochemical features controlling binding and the intrinsic-activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference t</context></contexts></citation><citation id="28487"><authors>P W Codding,A W Roszak,M B Szkaradzinska,J M Cook,T J Hagen</authors><year>1995</year><pages>499--512</pages><volume>73</volume><raw>Codding, P. W., Roszak, A. W., Szkaradzinska, M. B., Cook, J. M., Hagen, T. J. &amp; Allen, M. S. (1995). Can. J. Chem. 73, 499±512.</raw><contexts><context>ing and the intrinsic-activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference to the stereochemical model for the drug±receptor interaction we prop</context><context>ivity [DMCM (IAG: Bertolasi et al., 1990); Abecarnil (pAG: Bock et al., 1994); - CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from the Cambridge Crystallographic Database (Allen, 2002) and by the structures of -CCE (IAG), 6-PBC (pAG) PRCC and ZK93426 (both ANTs), which, not being available as crystal structures,</context><context>EKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Binding of -carbolines 483sresearch papers Bertolasi et al., 1990; YERRUI, 01,02 (Abecarnil): Bock et al., 1994; ZERHOT, ZERHUT, Codding et al., 1995)], sketched in (II), display some activity with respect to the BDZ receptor. The Free±Wilson method (Free &amp; Wilson, 1964) is a multiple regression technique for the quanti®cation of structure±activit</context><context>d that the oxygen is involved in a hydrogen bond [see (Ia), D2], being located in the same zone as the N atom of the diazepinic ring. This hypothesis is con®rmed by the fact that the ZERHOT molecule (Codding et al., 1995), substituted in 6 by a NHÐCH2ÐPh group but with no substituent in position 4, is found to act as an antagonist. (iii) All molecules are substituted in position 3 with ester groups carrying a linear </context></contexts></citation><citation id="28488"><authors>P W Codding,M B Szkaradzinska,A W Roszak</authors><year>1988</year><pages>2981--2988</pages><volume>66</volume><raw>Codding, P. W., Szkaradzinska, M. B., Roszak, A. W. &amp; Aha, L. J. (1988). Can. J. Chem. 66, 2981±2988.</raw><contexts><context>d by the X-ray structures of other carbolines of known biological activity [DMCM (IAG: Bertolasi et al., 1990); Abecarnil (pAG: Bock et al., 1994); - CCM (IAG: Bertolasi et al., 1984); -CC t Bu (ANT: Codding et al., 1988), ZERHOT and ZERHUZ (ANT and IAG, respectively: Codding et al., 1995)] retrieved from the Cambridge Crystallographic Database (Allen, 2002) and by the structures of -CCE (IAG), 6-PBC (pAG) PRCC and Z</context><context>3 version; Allen, 2002), from which seven compounds [CITRIG01,02,10 ( -CCM): Bertolasi et al., 1984; Kubicki &amp; Codding, 2001; Muir &amp; Codding, 1985; CITROM10: Muir &amp; Codding, 1984; JAFFIF ( -CC t Bu): Codding et al., 1988; SEKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Binding of -carbolines 483sresearch papers Bertolasi et al., 1990; YERRUI, 01,02 (Abecarnil): Bock et al., 1994; ZERHOT, ZERHU</context><context>y, this bifurcated bond is the most common in 3-substituted carboline crystals, as it occurs in the structures of Abecarnil, DMCM (Bertolasi et al., 1990), -CCM (Bertolasi et al., 1984) and -CC t Bu (Codding et al., 1988); consequently, it can be argued that a similar interaction could play a role in the ligand±receptor binding. In (3) (FG7142) the 3-R moiety is replaced by a CONHCH3 group which is almost perfectly c</context></contexts></citation><citation id="28489"><authors>M Davies,A N Bateson</authors><venue>J. Neurochem</venue><venType>JOURNAL</venType><year>1998</year><pages>2188--2194</pages><volume>70</volume><raw>Davies, M., Bateson, A. N. &amp; Dunn, S. M. J. (1998). J. Neurochem. 70, 2188±2194.</raw></citation><citation id="28490"><authors>G Dorey,G Poissonnet,Potier</authors><year>1989</year><pages>1799--1804</pages><editors>M. C., Prado de Carvalho, L., Verrault, P., Chapouthier, G., Rossier, J., Potier, P. &amp; Dodd, R. H</editors><volume>32</volume><raw>Dorey, G., Poissonnet, G., Potier, M. C., Prado de Carvalho, L., Verrault, P., Chapouthier, G., Rossier, J., Potier, P. &amp; Dodd, R. H. (1989). J. Med. Chem. 32, 1799±1804.</raw><contexts><context> the great majority of crystal structures so far determined (the only exception being DMCM: Bertolasi et al., 1990) and because it is generally believed to be the active conformation in drug binding (Dorey et al., 1989). 3. Results and discussion 3.1. Structural results ORTEPIII (Burnett &amp; Johnson, 1996) views of the four structures, oriented according to (I), are shown in Figs. 1±4 and the packing schemes are show</context><context>act forming between N(amide)-H and -carboline N1 atom, as clearly indicated by the structures of FG7142 (Fig. 2) and CITROM10 (Muir &amp; Codding, 1984), in agreement with previous experimental evidence (Dorey et al., 1989) that constrained -carbolines having the carbonyl in an anti conformation bind much less than the normal compounds. The most interesting substituents in position 6 from a pharmacological point of vie</context></contexts></citation><citation id="28491"><authors>S M J Dunn,M Davies,A L Muntoni</authors><year>1999</year><pages>768--774</pages><volume>56</volume><raw>Dunn, S. M. J., Davies, M., Muntoni, A. L. &amp; Lambert, J. J. (1999). Mol. Pharmacol. 56, 768±774.</raw><contexts><context> Accepted 4 June 2004 Acta Cryst. (2004). B60, 481±489 DOI: 10.1107/S0108768104013564 481sresearch papers receptors (Buhr et al., 1997; Schaerer et al., 1998; Davies et al., 1998; Sigel et al., 1998; Dunn et al., 1999; Renard et al., 1999; Strakhova et al., 2000; Newell et al., 2000). These experiments might eventually con®rm the previous structure±activity models which attempted to rationalize the stereochemical </context></contexts></citation><citation id="28492"><authors>L J Farrugia</authors><venue>J. Appl. Cryst</venue><venType>JOURNAL</venType><year>1999</year><pages>837--838</pages><volume>32</volume><raw>Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837±838.</raw><contexts><context>Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the SHELXL97 (Sheldrick, 1997) program. All other calculations were performed using the programs PLATON (Spek, 2001), WinGX (Farrugia, 1999) and PARST (Nardelli, 1995). ORTEPIII (Burnett &amp; Johnson, 1996) views of (1)±(4), oriented according to (I), are shown in Figs. 1±4. Hydrogen-bonding parameters for the four structures are reported i</context></contexts></citation><citation id="28493"><authors>H D Flack</authors><venue>Acta Cryst</venue><venType>JOURNAL</venType><year>1983</year><pages>876--881</pages><volume>39</volume><raw>Flack, H. D. (1983). Acta Cryst. A39, 876±881.</raw></citation><citation id="28494"><authors>S M Free</authors><year>1964</year><pages>395--399</pages><editors>J. Med. Chem</editors><volume>7</volume><raw>Free, S. M. &amp; Wilson, J. W. (1964). J. Med. Chem. 7, 395±399.</raw></citation><citation id="28495"><authors>S Gessi,A Dalpiaz,K Varani</authors><venue>Life Sci</venue><venType>JOURNAL</venType><year>1999</year><pages>185--192</pages><volume>64</volume><raw>Gessi, S., Dalpiaz, A., Varani, K. &amp; Borea, P. A. (1999). Life Sci. 64, 185±192.</raw><contexts><context>contributions aij for each substituent i at the different positions j. This model has been applied to the analysis of the activity data of 32 - carbolines (Hollinshead et al., 1990; Cox et al., 1998; Gessi et al., 1999), all concerning binding inhibition constants of radiolabelled ligands on rat cerebella membranes. Calculations were performed with a modi®ed version (Gilli, 2001) of the program originally proposed </context></contexts></citation><citation id="28496"><authors>G Gilli</authors><title>A Fortran Computer Program for Free-Wilson Analysis</title><year>2001</year><raw>Gilli, G. (2001). A Fortran Computer Program for Free-Wilson Analysis. Department of Chemistry, University of Ferrara, Italy.</raw><contexts><context> al., 1990; Cox et al., 1998; Gessi et al., 1999), all concerning binding inhibition constants of radiolabelled ligands on rat cerebella membranes. Calculations were performed with a modi®ed version (Gilli, 2001) of the program originally proposed by Purcell et al. (1973). The af®nity data of the 32 -carbolines, variously substituted in positions 1, 3±7 and employed in the Free±Wilson analysis together with </context></contexts></citation><citation id="28497"><authors>G Gilli,V Bertolasi,M Sacerdoti</authors><title>Acta Cryst. B34, 2826±2829. research papers</title><year>1978</year><pages>10405--10417</pages><volume>122</volume><raw>Gilli, G., Bertolasi, V., Sacerdoti, M. &amp; Borea, P. A. (1978). Acta Cryst. B34, 2826±2829. research papers Gilli, P., Bertolasi, V., Ferretti, V. &amp; Gilli, G. (2000). J. Am. Chem. Soc. 122, 10405±10417.</raw><contexts><context>2 H 0.19 0.77 1.11 1.36 1.93 1.93 OCH2-1-Napht O(CH2) 7CH3 0.57 2.04 aij = 0.10 2.78 0.23 0.25 2.83 0.20 phobic region, as it is shown by the superimposition of the full agonist ZK93423 and Oxazepam (Gilli et al., 1978) of Fig. 9. In Fig. 9(a) the crystallographic structures are reported, while in Fig. 9(b) the two molecules are shown after a ¯exible alignment procedure (Molecular Operating Environment, 2003) that </context></contexts></citation><citation id="28498"><authors>D L Harris</authors><venue>Bioorg. Med. Chem</venue><venType>JOURNAL</venType><year>2000</year><pages>2527--2538</pages><volume>8</volume><raw>Harris, D. L. &amp; Loew, G. (2000). Bioorg. Med. Chem. 8, 2527±2538.</raw></citation><citation id="28499"><authors>S P Hollinshead,M L Trudell,P Skolnick</authors><year>1990</year><pages>J.</pages><raw>Hollinshead, S. P., Trudell, M. L., Skolnick, P. &amp; Cook, J. M. (1990). J.</raw><contexts><context> features controlling binding and the intrinsic-activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference to the stereochemical model for the drug±recept</context><context>the pharmacophore) and the individual group contributions aij for each substituent i at the different positions j. This model has been applied to the analysis of the activity data of 32 - carbolines (Hollinshead et al., 1990; Cox et al., 1998; Gessi et al., 1999), all concerning binding inhibition constants of radiolabelled ligands on rat cerebella membranes. Calculations were performed with a modi®ed version (Gilli, 200</context></contexts></citation><citation id="28500"><authors>G A Jeffrey</authors><title>Hydrogen Bonding in Biological Structures</title><year>1991</year><publisher>Springer-Verlag</publisher><pubAddress>Berlin</pubAddress><raw>Jeffrey, G. A &amp; Saenger, W. (1991). Hydrogen Bonding in Biological Structures. Berlin: Springer-Verlag.</raw></citation><citation id="28501"><authors>P W Codding</authors><venue>Acta Cryst</venue><venType>JOURNAL</venType><year>2001</year><pages>728--731</pages><volume>57</volume><raw>Kubicki, M. &amp; Codding, P. W. (2001). Acta Cryst. C57, 728±731.</raw><contexts><context>line structures have been retrieved from the Cambridge Structural Database (September 2003 version; Allen, 2002), from which seven compounds [CITRIG01,02,10 ( -CCM): Bertolasi et al., 1984; Kubicki &amp; Codding, 2001; Muir &amp; Codding, 1985; CITROM10: Muir &amp; Codding, 1984; JAFFIF ( -CC t Bu): Codding et al., 1988; SEKPUT (DMCM): Acta Cryst. (2004). B60, 481±489 Valeria Ferretti et al. Binding of -carbolines 483sres</context></contexts></citation><citation id="28502"><authors>R M McKernan</authors><venue>TINS</venue><venType>JOURNAL</venType><year>1996</year><pages>139--143</pages><volume>19</volume><raw>McKernan, R. M. &amp; Whiting, P. J. (1996). TINS, 19, 139±143.</raw></citation><citation id="28503"><title>Molecular Operating Environment (2003). Release 2003.02</title><venue>MOE, Chemical Computing Group Inc</venue><venType>JOURNAL</venType><pubAddress>Montreal, Canada</pubAddress><raw>Molecular Operating Environment (2003). Release 2003.02. MOE, Chemical Computing Group Inc., Montreal, Canada.</raw></citation><citation id="28504"><authors>A K S Muir</authors><year>1984</year><pages>1803--1806</pages><volume>62</volume><raw>Muir, A. K. S. &amp; Codding, P. W. (1984). Can. J. Chem. 62, 1803±1806.</raw></citation><citation id="28505"><authors>A K S Muir</authors><year>1985</year><pages>2752--2755</pages><volume>63</volume><raw>Muir, A. K. S. &amp; Codding, P. W. (1985). Can. J. Chem. 63, 2752±2755.</raw><contexts><context>o rationalize the stereochemical features controlling binding and the intrinsic-activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference t</context></contexts></citation><citation id="28506"><authors>M Nardelli</authors><venue>J. Appl. Chem</venue><venType>JOURNAL</venType><year>1995</year><pages>65--9</pages><volume>28</volume><raw>Nardelli, M. (1995). J. Appl. Chem. 28, 659.</raw><contexts><context>er programs used: Kappa CCD server software (Nonius, 1997), DENZO-SMN (Otwinowski &amp; Minor, 1997), SIR97 (Altomare et al., 1999), SHELXL97 (Sheldrick, 1997), ORTEPIII (Burnett &amp; Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the SHELXL97 (Sheldrick, 1997) program. All other calculations were performed using the programs PLATON (Spek, 2001), WinGX (Farrugia, 1999) and PARST (Nardelli, </context></contexts></citation><citation id="28507"><authors>N Nayeem,T P Green,I L Martin</authors><venue>J. Neurochem</venue><venType>JOURNAL</venType><year>1994</year><pages>815--818</pages><volume>62</volume><raw>Nayeem, N., Green, T. P., Martin, I. L. &amp; Barnard, E. A. (1994). J. Neurochem. 62, 815±818.</raw><contexts><context>the negative effects of inverse agonists. The GABAA receptor is a member of the family of ligandgated ion channels (LGIC) and its detailed structure is presently unknown. Electron microscopy studies (Nayeem et al., 1994) have shown that, in analogy with the other members of the LGIC family, it has a pentameric quaternary structure formed by homologous subunits assembled to form a central channel. Many present studie</context></contexts></citation><citation id="28508"><authors>Nonius</authors><venue>Kappa-CCD Server Software. Nonius BV</venue><venType>JOURNAL</venType><year>1997</year><pubAddress>Delft, The Netherlands</pubAddress><raw>Nonius (1997). Kappa-CCD Server Software. Nonius BV, Delft, The Netherlands.</raw><contexts><context>c )/3 0.002 Ê Absolute structure 3 ) 0.38, 0.28 Flack (1983) 0.18, 0.18 Flack (1983) 0.18, 0.19 ± 0.28, 0.36 ± Flack parameter 1.4 (13) 1.7 (15) ± ± Computer programs used: Kappa CCD server software (Nonius, 1997), DENZO-SMN (Otwinowski &amp; Minor, 1997), SIR97 (Altomare et al., 1999), SHELXL97 (Sheldrick, 1997), ORTEPIII (Burnett &amp; Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the S</context></contexts></citation><citation id="28509"><authors>Z Otwinowski</authors><venue>Methods Enzymol</venue><venType>JOURNAL</venType><year>1997</year><pages>32--6</pages><volume>276</volume><raw>Otwinowski, Z. &amp; Minor, W. (1997). Methods Enzymol. 276, 307± 326.</raw></citation><citation id="28510"><authors>S Renard,A Olivier,P Granger,P Avenet,D Graham,M Sevrin,P George</authors><venue>J. Biol. Chem</venue><venType>JOURNAL</venType><year>1999</year><pages>1337--4</pages><volume>274</volume><raw>Renard, S., Olivier, A., Granger, P., Avenet, P., Graham, D., Sevrin, M., George, P. &amp; Besnard, F. (1999). J. Biol. Chem, 274, 13370± 13374.</raw><contexts><context>04 Acta Cryst. (2004). B60, 481±489 DOI: 10.1107/S0108768104013564 481sresearch papers receptors (Buhr et al., 1997; Schaerer et al., 1998; Davies et al., 1998; Sigel et al., 1998; Dunn et al., 1999; Renard et al., 1999; Strakhova et al., 2000; Newell et al., 2000). These experiments might eventually con®rm the previous structure±activity models which attempted to rationalize the stereochemical features controlling </context></contexts></citation><citation id="28511"><authors>M T Schaerer,A Buhr,R Baur</authors><venue>Eur. J. Pharmacol</venue><venType>JOURNAL</venType><year>1998</year><pages>283--287</pages><volume>354</volume><raw>Schaerer, M. T., Buhr, A., Baur, R. &amp; Sigel, E. (1998). Eur. J. Pharmacol. 354, 283±287.</raw><contexts><context> by means of af®nity experiments on mutated Received 20 May 2004 Accepted 4 June 2004 Acta Cryst. (2004). B60, 481±489 DOI: 10.1107/S0108768104013564 481sresearch papers receptors (Buhr et al., 1997; Schaerer et al., 1998; Davies et al., 1998; Sigel et al., 1998; Dunn et al., 1999; Renard et al., 1999; Strakhova et al., 2000; Newell et al., 2000). These experiments might eventually con®rm the previous structure±activi</context></contexts></citation><citation id="28512"><authors>G M Sheldrick</authors><year>1997</year><pubAddress>ttingen, Germany</pubAddress><raw>Sheldrick, G. M. (1997). SHELX97. University of GoÈ ttingen, Germany.</raw><contexts><context>9 ± 0.28, 0.36 ± Flack parameter 1.4 (13) 1.7 (15) ± ± Computer programs used: Kappa CCD server software (Nonius, 1997), DENZO-SMN (Otwinowski &amp; Minor, 1997), SIR97 (Altomare et al., 1999), SHELXL97 (Sheldrick, 1997), ORTEPIII (Burnett &amp; Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the SHELXL97 (Sheldrick, 1997) program. All other calculations were performed using the programs PLATO</context></contexts></citation><citation id="28513"><authors>E Sigel,M T Schaerer,A Buhr</authors><year>1998</year><pages>1097--1105</pages><volume>54</volume><raw>Sigel, E., Schaerer, M. T., Buhr, A. &amp; Baur, R. (1998). Mol. Pharmacol. 54, 1097±1105.</raw><contexts><context>Received 20 May 2004 Accepted 4 June 2004 Acta Cryst. (2004). B60, 481±489 DOI: 10.1107/S0108768104013564 481sresearch papers receptors (Buhr et al., 1997; Schaerer et al., 1998; Davies et al., 1998; Sigel et al., 1998; Dunn et al., 1999; Renard et al., 1999; Strakhova et al., 2000; Newell et al., 2000). These experiments might eventually con®rm the previous structure±activity models which attempted to rationalize </context></contexts></citation><citation id="28514"><authors>A L Spek</authors><year>2001</year><raw>Spek, A. L (2001). PLATON. Utrecht University, The Netherlands.</raw><contexts><context>CD server software (Nonius, 1997), DENZO-SMN (Otwinowski &amp; Minor, 1997), SIR97 (Altomare et al., 1999), SHELXL97 (Sheldrick, 1997), ORTEPIII (Burnett &amp; Johnson, 1996), PARST (Nardelli, 1995), PLATON (Spek, 2001). H atoms using the SHELXL97 (Sheldrick, 1997) program. All other calculations were performed using the programs PLATON (Spek, 2001), WinGX (Farrugia, 1999) and PARST (Nardelli, 1995). ORTEPIII (Burn</context></contexts></citation><citation id="28515"><authors>Tripos Inc</authors><venue>Alchemy32, Version 2.0. Tripos Inc</venue><venType>CONFERENCE</venType><year>1997</year><pubAddress>St. Louis, Missouri, USA</pubAddress><raw>Tripos Inc. (1997). Alchemy32, Version 2.0. Tripos Inc., St. Louis, Missouri, USA.</raw></citation><citation id="28516"><authors>W Zhang,K F Koehler,P Zhang</authors><title>Drug Des</title><venue>Discov</venue><venType>JOURNAL</venType><year>1995</year><pages>193--248</pages><volume>12</volume><raw>Zhang, W., Koehler, K. F., Zhang, P. &amp; Cook, J. M. (1995). Drug Des. Discov. 12, 193±248.</raw><contexts><context>activity properties of the BDZ±receptor ligands in order to map the receptor binding site (Loew et al., 1984; Codding &amp; Muir, 1985; Borea et al., 1987; Hollinshead et al., 1990; Codding et al., 1995; Zhang et al., 1995; Cox et al., 1998; Harris &amp; Loew, 2000; Marder et al., 2001). In this discussion we make particular reference to the stereochemical model for the drug±receptor interaction we proposed in 1987 (Borea </context></contexts></citation></citations><fileInfo><url>http://journals.iucr.org/b/issues/2004/04/00/na5019/na5019.pdf</url><repID>rep1</repID><conversionTrace>PDFLib TET</conversionTrace><checkSums><checkSum><fileType>pdf</fileType><sha1>5a6c6b67b9a86861ca6e54bf9e7506bc4cb46f02</sha1></checkSum></checkSums></fileInfo></document>